Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Mitsubishi Tanabe’s Buyout Program Has No Bearing on Potential Divestment: EVP
The recently announced launch of a voluntary redundancy program at Mitsubishi Tanabe Pharma has “no relation whatsoever” with its potential divestiture from Mitsubishi Chemical Group being mulled by the parent firm, a top official said. Akihiro Tsujimura, executive vice president…
To read the full story
Related Article
- Mitsubishi Tanabe’s Net Profit More than Halves after Buyout Package
May 14, 2025
- Mitsubishi Chemical Looking for “Best Partners” for Pharma Biz: CEO
November 14, 2024
- Mitsubishi Tanabe Sales Up 6% on Radicava Oral Form
November 5, 2024
- Mitsubishi Chemical Denies Media Report on Pharma Divestiture
September 9, 2024
- Mitsubishi Tanabe to Launch Voluntary Buyout Program
July 30, 2024
- Mitsubishi Tanabe’s Earnings Sink 2-Digits in FY2023 on Backlash from Previous Gilenya Royalties
May 17, 2024
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…